Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Alcohol Use Disorders
NCT03636555Phase 2Withdrawn
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Oct 2019
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in alcohol use disorder (AUD) (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Percentage of heavy drinking days at 12 weeks, Percentage of abstinent days at 12 weeks and 1 more. Planned start Oct 2019; status: withdrawn.
02
Drugs
oxytocin nasal spray
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03636555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636555.